Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy

Table 3 Crohn’s disease vs ulcerative colitis pre-anti-tumour necrosis factor therapy

	CD (n = 13) (n or mean ± SEM)	UC (n = 5) (n or mean ± SEM)	P value
Immunosuppressant
Thiopurine	10	4	NS
Tacrolimus	0	0
Prednisone	6	4	NS
Prednisone/thiopurine	3	3
Methotrexate	0	0
5-ASA	2	3	NS
ESR	17.4 ± 3.3 (n = 11)	27.6 ± 11.8 (n = 4)	NS
CRP	19.5 ± 6.3 (n = 13)	29.8 ± 12 (n = 4)	NS
Partial Mayo1 (out of 9 - UC patients only)	-	8.5 ± 0.9 (n = 4)
CDAI (CD patients only)	337 ± 29.8 (n = 12)	-

¹Partial Mayo scores were presented, as not all patients had undergone endoscopic examination at time of blood draw. CD: Crohn’s disease; CDAI: Crohn’s disease activity index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; UC: Ulcerative colitis.